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A bs tr ac t
BACKGROUND
Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, 
delays the emergence of resistance and reduces toxic effects in patients who have 
melanoma with BRAF V600E or V600K mutations.
METHODS
In this phase 3 trial, we randomly assigned 423 previously untreated patients who 
had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K 
mutation to receive a combination of dabrafenib (150 mg orally twice daily) and 
trametinib (2 mg orally once daily) or dabrafenib and placebo. The primary end 
point was progression-free survival. Secondary end points included overall survival, 
response rate, response duration, and safety. A preplanned interim overall survival 
analysis was conducted.
RESULTS
The median progression-free survival was 9.3 months in the dabrafenib–trametinib 
group and 8.8 months in the dabrafenib-only group (hazard ratio for progression 
or death in the dabrafenib–trametinib group, 0.75; 95% confidence interval [CI], 
0.57 to 0.99; P = 0.03). The overall response rate was 67% in the dabrafenib–tra-
metinib group and 51% in the dabrafenib-only group (P = 0.002). At 6 months, the 
interim overall survival rate was 93% with dabrafenib–trametinib and 85% with 
dabrafenib alone (hazard ratio for death, 0.63; 95% CI, 0.42 to 0.94; P = 0.02). How-
ever, a specified efficacy-stopping boundary (two-sided P = 0.00028) was not 
crossed. Rates of adverse events were similar in the two groups, although more 
dose modifications occurred in the dabrafenib–trametinib group. The rate of cuta-
neous squamous-cell carcinoma was lower in the dabrafenib–trametinib group 
than in the dabrafenib-only group (2% vs. 9%), whereas pyrexia occurred in more 
patients (51% vs. 28%) and was more often severe (grade 3, 6% vs. 2%) in the dab-
rafenib–trametinib group.
CONCLUSIONS
A combination of dabrafenib and trametinib, as compared with dabrafenib alone, 
improved the rate of progression-free survival in previously untreated patients who 
had metastatic melanoma with BRAF V600E or V600K mutations. (Funded by Glaxo-
SmithKline; Clinical Trials.gov number, NCT01584648.)
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Targeted inhibition of the RAF–MEK–ERK (MAPK) pathway with BRAF inhibitors dabrafenib or vemurafenib, as compared 
with chemotherapy, improves the progression-
free and overall survival of patients who have 
metastatic melanoma with BRAF V600 muta-
tions.1,2 However, resistance develops in a major-
ity of patients, resulting in a median progression-
free survival of 6 to 7 months.3,4 Most reported 
resistance mechanisms reactivate the MAPK path-
way.5-7 In addition, BRAF-inhibitor–induced para-
doxical activation of the MAPK pathway8-10 can 
result in secondary cancers, including cutaneous 
squamous-cell carcinoma, and may reactivate 
RAS-mutant tumors.11-13 Independently, single-
agent trametinib, a MEK inhibitor, improves the 
overall survival of patients with BRAF V600 muta-
tion–positive metastatic melanoma, as compared 
with chemotherapy, and is not associated with 
paradoxical activation.14
The combination of BRAF and MEK inhibi-
tion, as compared with single-agent BRAF inhi-
bition, delayed the emergence of resistance and 
decreased the incidence of cutaneous hyperpro-
liferative lesions in preclinical models.12,15,16 This 
finding was confirmed in an unblinded, ran-
domized, phase 2 study of a combination of 
dabrafenib and trametinib, as compared with 
dabrafenib alone, with crossover permitted at 
the time of disease progression for those receiv-
ing dabrafenib alone.17 The median progression-
free survival was 9.4 months with combination 
therapy versus 5.8 months with dabrafenib alone 
(hazard ratio for progression or death in the 
dabrafenib–trametinib group, 0.39; 95% confi-
dence interval [CI], 0.25 to 0.62; P<0.001) and 
the corresponding response rate was 76% versus 
54% (P = 0.03).17 The rate of cutaneous squamous-
cell carcinoma was lower in the dabrafenib–tra-
metinib group than in the dabrafenib-only group 
(7% vs. 19%).
We conducted a double-blind, randomized, 
phase 3 study without crossover to compare the 
combination of dabrafenib and trametinib with 
dabrafenib alone as first-line therapy in patients 
who had metastatic melanoma with BRAF V600E 
or V600K mutations.
Me thods
Patients
Eligible patients had histologically confirmed, 
unresectable stage IIIC or stage IV metastatic 
melanoma with BRAF V600E or V600K mutations, 
as determined by means of an investigational-
use-only polymerase-chain-reaction assay (ThxID 
BRAF Assay, bioMérieux) performed at a central 
reference laboratory. Patients were not eligible if 
they had previous systemic anticancer therapy 
(including BRAF or MEK inhibitors). Patients 
with brain metastases that had been definitively 
treated and stable for at least 12 weeks were eli-
gible to participate. Additional inclusion and ex-
clusion criteria are provided in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org. Written informed consent 
was obtained from all study patients.
Study Design and Treatments
From May 2012 through January 2013, we 
screened 947 patients at 113 centers worldwide. 
We randomly assigned 423 of these patients, in a 
1:1 ratio, to receive either a combination of oral 
dabrafenib (150 mg twice daily) and oral tra-
metinib (2 mg once daily) or oral dabrafenib 
(150 mg twice daily) and placebo. Patients were 
stratified according to the baseline lactate dehy-
drogenase level and BRAF genotype (Fig. S1 in 
the Supplementary Appendix).
Study End Points
The primary end point was investigator-assessed 
progression-free survival, defined as the time 
from randomization until radiologic disease pro-
gression or death from any cause. The secondary 
end points were overall survival, response rate, 
response duration, safety, and pharmacokinetics, 
as defined in the Supplementary Appendix. An 
independent central review committee whose 
members were unaware of study-group assign-
ments reviewed radiologic findings on which a 
sensitivity analysis of progression-free survival 
was based. No interim analyses were performed 
for efficacy or futility with respect to the primary 
end point.
Study Assessments
Tumor assessments were conducted according to 
Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1,18 at baseline, at week 8, 
every 8 weeks until week 56, and then every 12 
weeks until disease progression, death, or with-
drawal from the study. Patients who were eligible 
for continued treatment beyond progression un-
derwent tumor assessments according to the 
protocol. (Eligibility criteria for this assessment 
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are provided in the Supplementary Appendix.) All 
responses were confirmed on either computed 
tomography or magnetic resonance imaging, 
with scanning obtained at least 4 weeks after the 
first RECIST response. Adverse events were grad-
ed by the site investigator according to the Na-
tional Cancer Institute Common Terminology Cri-
teria for Adverse Events, version 4.0,19 throughout 
the study until 30 days after the discontinuation 
of study treatment.
Study Oversight
This study was funded by the sponsor, Glaxo-
SmithKline. The protocol was approved by the in-
stitutional review board or human research ethics 
committee at each participating center and com-
Table 1. Characteristics of the Patients at Baseline (Intention-to-Treat Population).*
Characteristic
Dabrafenib  
plus Trametinib  
(N = 211)
Dabrafenib 
Alone  
(N = 212)
All Patients  
(N = 423)
Median age (range) — yr 55.0 (22–89) 56.5 (22–86) 56.0 (22–89)
Male sex — no. (%) 111 (53)   114 (54)   225 (53)
Previous immunotherapy — no./total no. (%) 56/210 (27) 61/211 (29) 117/421 (28)
ECOG performance score — no./total no. (%)†
0 155/210 (74) 150/211 (71) 305/421 (72)
1 55/210 (26) 61/211 (29) 116/421 (28)
BRAF mutation — no. (%)‡
V600E 179 (85) 181 (85) 360 (85)
V600K 32 (15) 30 (14) 62 (15)
Tumor stage — no. (%)§
IVM1c 142 (67) 138 (65) 280 (66)
IIIc, IVM1a, or IVM1b 69 (33) 73 (34) 142 (34)
Metastasis stage — no. (%)
M0 5 (2) 10 (5) 15 (4)
M1a 19 (9) 31 (15) 50 (12)
M1b 45 (21) 32 (15) 77 (18)
M1c 142 (67) 138 (65) 280 (66)
Lactate dehydrogenase level — no./total no. (%)
>ULN 77/210 (37) 71/211 (34) 148/421 (35)
≤ULN 133/210 (63) 140/211 (66) 273/421 (65)
Visceral disease — no. (%)¶
Yes 165 (78) 145 (68) 310 (73)
No 46 (22) 66 (31) 112 (26)
Number of disease sites — no./total no. (%)||
≤2 109/210 (52) 119/211 (56) 228/421 (54)
≥3 101/210 (48) 92/211 (44) 193/421 (46)
* In the dabrafenib–trametinib group, 1 patient underwent randomization in error, and no baseline data were recorded 
for this patient in four of the listed categories (total number of patients in these categories, 210). In the dabrafenib-only 
group, 1 patient underwent randomization in error, and no baseline data were entered for this patient in any listed cate-
gory (total number of patients in all categories, 211). There were no significant differences between the groups. ULN 
denotes upper limit of the normal range.
† Eastern Cooperative Oncology Group (ECOG) performance status ranges from 0 to 5, with higher numbers indicating 
increasing impairment in activities of daily living.
‡ A patient with both BRAF V600E and V600K mutations was included in the V600K subgroup.
§ The extent of metastatic melanoma is described as the American Joint Committee on Cancer stage.
¶ Visceral disease was defined as metastasis to the soft internal organs, including the lungs, heart, and the organs of the 
digestive, excretory, reproductive, and circulatory systems but excluding lymph nodes.
‖ This category refers to the number of unique target and nontarget sites that were identified by the investigator on the 
basis of Response Evaluation Criteria in Solid Tumors (RECIST) rather than the number of metastases.
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plied with country-specific regulatory require-
ments. The study was conducted in accordance 
with the provisions of the Declaration of Helsin-
ki and Good Clinical Practice guidelines. The 
first and last authors and representatives of the 
sponsor designed the study. Data collection was 
performed by staff members employed at each 
study site and was monitored by the sponsor. The 
first author wrote the initial drafts of the manu-
script, with support from the last author and rep-
resentatives of the sponsor. All authors and spon-
sor representatives had full access to the study 
data and were involved in the data analysis. All 
the authors made the decision to submit the 
manuscript for publication and vouch for the ac-
curacy of the data and the fidelity of the study to 
the protocol, which is available at NEJM.org. No 
one who is not listed as an author contributed to 
the writing of the manuscript.
Statistical Analysis
This report is based on data as of August 2013, 
when the prespecified number of disease pro-
gressions or deaths (whichever came first) had oc-
curred. The study was initially designed with a 
power of more than 90% to detect a 41% reduc-
tion in the risk of disease progression or death 
(hazard ratio, 0.59) in the dabrafenib–trametinib 
group, as compared with the dabrafenib-only 
group, at a one-sided type I error rate of 0.025. 
The study was overenrolled by approximately 
24% (423 actual enrollees vs. the target of 340). 
To increase the precision of the median progres-
sion-free survival estimate in the dabrafenib–tra-
metinib group, the final analysis was planned 
after 193 events had occurred, which maintained 
the same ratio of events to patients as originally 
planned. As a result, the power increased from 
90% to 95%. A prespecified interim analysis of 
overall survival was planned at the time of the 
analysis of progression-free survival. The stop-
ping boundary for the interim analysis of overall 
survival was a two-sided alpha level of less than 
0.00028. A final overall survival analysis will be 
conducted when 70% of the patients who under-
went randomization have died or been lost to 
follow-up.
We used a Kaplan–Meier analysis to estimate 
progression-free and overall survival, and treat-
ment comparisons were made with the use of a 
stratified log-rank test. Post hoc subgroup analy-
ses were performed with the use of an unstrati-
fied log-rank test. Efficacy was determined in all 
patients in the intention-to-treat population; safe-
ty analyses were performed in all patients who 
received at least one dose of a study drug. Treat-
ment beyond progression was defined as the 
receipt of a study drug more than 15 days after 
radiologic progression, as defined by RECIST.
R esult s
Patients
Of 947 patients who were screened, 423 patients 
were randomly assigned to receive either dab-
rafenib plus trametinib (211 patients) or dab-
rafenib plus placebo (212 patients) (Table 1, and 
Fig. S1 in the Supplementary Appendix). The lack 
of a BRAF V600E or V600K mutation was the most 
common reason for exclusion (in 245 patients). 
Baseline characteristics were similar in the two 
study groups (Table 1). The median follow-up 
time was 9 months (range, 0 to 16). Details of 
patient status and follow-up are provided in Fig-
ure S1 in the Supplementary Appendix.
Efficacy
In the intention-to-treat population, the estimat-
ed median progression-free survival (the primary 
end point) was longer in the dabrafenib–tra-
metinib group than in the dabrafenib-only group 
(9.3 months vs. 8.8 months); the hazard ratio for 
disease progression or death was 0.75 (95% CI, 
0.57 to 0.99; P = 0.03) (Fig. 1A). The progression-
Figure 1 (facing page). Progression-free Survival  
and Subgroup Analyses.
Panel A shows Kaplan–Meier estimates of progres-
sion-free survival in the intention-to-treat population. 
Panel B shows hazard ratios and 95% confidence in-
tervals for progression-free survival in subgroup analy-
ses, according to baseline characteristics. One patient 
in each study group underwent randomization in er-
ror, so the number of patients in each category may 
not total the number in the intention-to-treat popula-
tion. Panel C shows Kaplan–Meier estimates of pro-
gression-free survival for patients with an elevated lac-
tate dehydrogenase level at baseline. The vertical lines 
indicate censoring of data. Eastern Cooperative Oncol-
ogy Group (ECOG) performance status ranges from  
0 to 5, with higher numbers indicating increasing im-
pairment in activities of daily living. LDH denotes lac-
tate dehydrogenase, and ULN upper limit of the nor-
mal range.
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free survival benefit favored ºthe dabrafenib–tra-
metinib group in most of the subgroups that 
were analyzed (Fig. 1B).
In patients with an elevated lactate dehydro-
genase level, the median progression-free survival 
was 7.1 months in the dabrafenib–trametinib 
group as compared with 3.8 months in the 
dabrafenib-only group (hazard ratio for disease 
progression or death, 0.64; 95% CI, 0.42 to 0.95), 
with 49 events in each group (64% vs. 69%) (Fig. 
1C). Among patients in the two study groups, 
there were fewer events in the subgroup with a 
normal lactate dehydrogenase level: 53 events 
(40%) in the dabrafenib–trametinib group ver-
sus 60 events (43%) in the dabrafenib-only group 
(hazard ratio, 0.83; 95% CI, 0.57 to 1.20) (Fig. 
S2A in the Supplementary Appendix).
Within the first 2 months after randomization, 
data for 6 patients in the dabrafenib–trametinib 
group and 18 patients in the dabrafenib-only 
group were censored in the progression-free sur-
vival analysis (for details, see the Results section 
in the Supplementary Appendix). Of the 18 pa-
tients in the dabrafenib-only group for whom 
data were censored, 13 had disease progression 
on the basis of clinical indications (without radio-
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Figure 2. Overall Survival.
Shown are Kaplan–Meier estimates of overall survival in the intention-to-treat population (Panel A) and in patients 
with an elevated lactate dehydrogenase level at baseline (Panel B). The vertical lines indicate censoring of data.
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logic confirmation), as determined by the inves-
tigator, or had started a new anticancer therapy. 
In preplanned sensitivity analyses, when clinical 
progression or initiation of a new anticancer 
therapy was considered as an event, the hazard 
ratio for progression and the median progres-
sion-free survival for the dabrafenib–trametinib 
group remained stable (i.e., the median remained 
the same when clinical progression was consid-
ered or decreased by 0.1 month when the initia-
tion of a new anticancer therapy was consid-
ered). In contrast, the median progression-free 
survival in the dabrafenib-only group decreased 
by 1.2 months when clinical progression was 
considered and by 1.6 months when the initia-
tion of a new anticancer therapy was considered 
(Table S1 in the Supplementary Appendix).
At the time of the interim survival analysis, 
40 patients (19%) in the dabrafenib–trametinib 
group and 55 patients (26%) in the dabrafenib-
only group had died (hazard ratio for death, 
0.63; 95% CI, 0.42 to 0.94; P = 0.02). At 6 months, 
the overall survival rate was 93% in the dab-
rafenib–trametinib group and 85% in the dab-
rafenib-only group. However, the between-group 
difference did not cross the prespecified stop-
ping boundary (two-sided P = 0.00028). At the 
time of this report, neither group had reached a 
median overall survival (Fig. 2A). Patients with 
an elevated lactate dehydrogenase level appeared 
to derive a greater survival benefit from combi-
nation therapy over monotherapy, with deaths of 
24 of 77 patients (31%) and 36 of 71 patients 
(51%), respectively. The median survival among 
patients with an elevated lactate dehydrogenase 
level receiving combination therapy was 13.7 
months versus 8.9 months among those receiving 
dabrafenib alone (hazard ratio for death, 0.48; 
95% CI, 0.29 to 0.80) (Fig. 2B). In contrast, among 
patients with a normal lactate dehydrogenase lev-
el, deaths were reported in only 16 of 133 patients 
(12%) receiving combination therapy and 19 of 
140 patients (14%) receiving dabrafenib alone 
(Fig. S2B in the Supplementary Appendix).
Response Rate
The overall response rate as assessed by investi-
gators was 67% (95% CI, 60 to 73) in the dab-
rafenib–trametinib group versus 51% (95% CI, 
45 to 58) in the dabrafenib-only group (P = 0.002) 
(Table 2). In the dabrafenib–trametinib group, 
22 patients (10%) had a complete response, and 
118 (56%) had a partial response. In the dab-
rafenib-only group, 18 (9%) had a complete re-
Table 2. Disease Response, According to the Type of BRAF Mutation.*
Variable BRAF V600E or V600K BRAF V600E BRAF V600K
Dabrafenib 
plus  
Trametinib 
(N = 210)
Dabrafenib 
Alone
(N = 210)
Dabrafenib 
plus 
Trametinib
(N = 179)
Dabrafenib 
Alone
(N = 180)
Dabrafenib 
plus 
Trametinib
(N = 31)
Dabrafenib 
Alone
(N = 30)
Best response — no. (%)
Complete response 22 (10) 18 (9) 19 (11) 16 (9) 3 (10) 2 (7)
Partial response 118 (56) 90 (43) 102 (57) 80 (44) 16 (52) 10 (33)
Stable disease 54 (26) 69 (33) 46 (26) 62 (34) 8 (26) 7 (23)
Progressive disease 13 (6) 19 (9) 10 (6) 11 (6) 3 (10) 8 (27)
Could not be evaluated 3 (1) 14 (7) 2 (1) 11 (6) 1 (3) 3 (10)
Complete or partial response†
No. of patients with response 140 108 121 96 19 12
Percentage (95% CI) 67 (60–73) 51 (45–58) 68 (60–74) 53 (46–61) 61 (42–78) 40 (23–59)
* Included in this analysis were the 210 patients in each study group who had measurable disease at baseline.
† The absolute difference in the rate of complete or partial response in the group receiving dabrafenib plus trametinib, as 
compared with the dabrafenib-only group, was 16 percentage points (95% CI, 6 to 25; P = 0.002) in patients with either 
BRAF mutation, 15 percentage points (95% CI, 4 to 24; P = 0.006) in those with the BRAF V600E mutation, and 21 per-
centage points (95% CI, −3 to 46; P = 0.10) in those with the BRAF V600K mutation. P values were calculated by means 
of the chi-square test.
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sponse, and 90 (43%) had a partial response. 
The median duration of response was 9.2 
months in the dabrafenib–trametinib group 
and 10.2 months in the dabrafenib-only group 
on the basis of data that were highly censored 
because the majority of investigator-assessed 
responses (60%) were still ongoing. Within 
each of the two study groups, the response rates 
were slightly lower in the BRAF V600K subgroup 
than in the predominant V600E subgroup (Ta-
ble 2).
Other Anticancer Therapies
Fewer patients in the dabrafenib–trametinib 
group than in the dabrafenib-only group received 
a second type of anticancer therapy (43 [20%] vs. 65 
[31%]) (Table S2 in the Supplementary Appendix). 
In contrast, more patients in the dabra fenib–
trametinib group than in the dabrafenib-only 
group continued treatment beyond progression 
(41 [19%]) vs. 34 [16%]), including at the time of 
data cutoff (19 [46%] vs. 7 [21%]). Ipilimumab 
was the most common subsequent anticancer 
Table 3. Adverse Events.*
Event
Dabrafenib plus Trametinib
(N = 209)
Dabrafenib Alone
(N = 211)
Any Grade† Grade 3 Any Grade† Grade 3
number of patients (percent)
Any adverse event 199 (95) 66 (32) 203 (96) 72 (34)
Pyrexia‡ 107 (51) 12 (6) 59 (28) 4 (2)
Fatigue 74 (35) 4 (2) 74 (35) 2 (1)
Headache 63 (30) 1 (<1) 62 (29) 3 (1)
Nausea 63 (30) 0 54 (26) 3 (1)
Chills 62 (30) 0 33 (16) 0
Arthralgia 51 (24) 1 (<1) 58 (27) 0
Diarrhea 51 (24) 2 (1) 30 (14) 2 (1)
Rash 48 (23) 0 46 (22) 2 (1)
Hypertension 46 (22) 8 (4) 29 (14) 10 (5)
Vomiting 42 (20) 2 (1) 29 (14) 1 (<1)
Cough 34 (16) 0 35 (17) 0
Peripheral edema 30 (14) 1 (<1) 10 (5) 1 (<1)
Pain in a limb 30 (14) 3 (1) 33 (16) 1 (<1)
Decreased appetite 23 (11) 1 (<1) 25 (12) 2 (1)
Abdominal pain 22 (11) 2 (1) 14 (7) 3 (1)
Elevated alanine aminotransferase 22 (11) 4 (2) 10 (5) 1 (<1)
Elevated aspartate aminotransferase 22 (11) 6 (3) 7 (3) 1 (<1)
Constipation 22 (11) 1 (<1) 18 (9) 0
Myalgia 22 (11) 1 (<1) 24 (11) 0
Asthenia 20 (10) 1 (<1) 27 (13) 1 (<1)
Dizziness 20 (10) 0 12 (6) 0
Nasopharyngitis 20 (10) 0 15 (7) 0
Back pain 19 (9) 2 (1) 30 (14) 4 (2)
Dry skin 19 (9) 0 28 (13) 0
Pruritus 17 (8) 0 26 (12) 0
Alopecia 15 (7) 0 55 (26) 0
Hand–foot syndrome§ 10 (5) 0 58 (27) 1 (<1)
Hyperkeratosis 7 (3) 0 68 (32) 1 (<1)
Skin papilloma 3 (1) 0 45 (21) 0
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therapy in the two groups; however, fewer pa-
tients in the dabrafenib–trametinib group than 
in the dabrafenib-only group received ipilimumab 
(19 [9%] vs. 32 [15%]). A similar number of pa-
tients in the two groups received subsequent 
therapy with vemurafenib: 12 (6%) in the dabra-
fenib–trametinib group and 13 (6%) in the dab-
rafenib-only group. No patients received mono-
clonal antibodies targeting programmed death 1 
and programmed death ligand 1.
Adverse Events
Among patients who received at least one dose of 
a study drug, permanent discontinuations were 
reported in 19 of 209 patients (9%) in the dab-
rafenib–trametinib group and 11 of 211 patients 
(5%) in the dabrafenib-only group. In addition, 
dose reductions were required in 52 patients 
(25%) and 28 patients (13%), respectively, and in-
terruption of a study drug because of adverse 
events occurred in 103 patients (49%) and 70 pa-
tients (33%), respectively. In both the dabrafenib–
trametinib group and the dabrafenib-only group, 
pyrexia was the most common reason for dose 
interruptions (in 67 patients [32%] and 28 pa-
tients [13%]) and dose reductions (in 27 patients 
[13%] and 6 patients [3%]). The most common 
reason for permanent discontinuation was pyrexia 
in the dabrafenib–trametinib group (in 5 patients 
[2%]) and a decreased ejection fraction in the 
dabrafenib-only group (in 3 patients [1%]).
The most common adverse events in the two 
study groups were pyrexia, fatigue, nausea, 
headache, chills, diarrhea, arthralgia, rash, and 
hypertension (Table 3). Fewer patients in the 
dabrafenib–trametinib group than in the dabra-
fenib-only group had incident cutaneous squa-
mous-cell carcinoma (2% vs. 9%) or cutaneous 
hyperkeratoses (3% vs. 32%). Papillomas, alope-
cia, and the hand–foot syndrome were also less 
common in the dabrafenib–trametinib group. 
However, pyrexia, hypertension, peripheral edema, 
and diarrhea were more common in the dabra-
fenib–trametinib group than in the dabrafenib-
only group (proportion of patients with pyrexia, 
51% vs. 28%) (Table 3, and Fig. S3 in the Supple-
mentary Appendix). There were no cases of 
retinal-vein occlusion. Of the 107 patients in the 
dabrafenib–trametinib group who had pyrexia, 
67 (63%) had a second episode, and 50 (47%) 
had three or more episodes. The median time 
to the onset of the first episode of pyrexia was 
4.3 weeks, and the median duration was 3 days. 
During an acute episode of pyrexia, 63% of pa-
Table 3. (Continued.)*
Event
Dabrafenib plus Trametinib
(N = 209)
Dabrafenib Alone
(N = 211)
Any Grade† Grade 3 Any Grade† Grade 3
number of patients (percent)
Adverse event of interest occurring in <10% of patients
Cutaneous squamous-cell carcinoma  
including keratoacanthoma
5 (2) 4 (2) 20 (9) 8 (4)
Decreased ejection fraction 9 (4) 1 (<1) 5 (2) 1 (<1)
Chorioretinopathy 1 (<1) 0 1 (<1) 0
Blurred vision 5 (2) 0 4 (2) 0
Dermatitis acneiform 16 (8) 0 7 (3) 0
* Listed are adverse events that occurred in at least 10% of patients who received at least one dose of a study drug in any 
group, except as indicated.
† A total of eight grade 4 events occurred in seven patients (3%) in the dabrafenib–trametinib group (anemia, decreased 
lymphocyte count, hypoglycemia, pulmonary embolism, brain edema, hepatic hematoma, metastases to central nervous 
system, and pancytopenia) and in seven patients (3%) in the dabrafenib-only group (dyspnea, thrombocytopenia, hypo-
kalemia, cutaneous squamous-cell carcinoma, brain edema, hypercalcemia, febrile neutropenia, and hypovolemic shock). 
Grade 5 events were reported in four patients (2%) in the dabrafenib–trametinib group (pneumonia and cerebral hem-
orrhage [in three patients]).
‡ Pyrexia was defined as a body temperature of 38.5°C or higher.
§ The hand–foot syndrome included the terms palmar–plantar erythrodysesthesia, palmar–plantar hyperkeratosis, and 
palmoplantar keratoderma.
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tients had a dose interruption and 25% had a 
dose reduction, with resolution of pyrexia in 
97% of the patients. Glucocorticoids were used 
for 3 weeks or more as prophylaxis for pyrexia 
in 30 patients in the dabrafenib–trametinib group 
after the first or second event. Pharmacokinetic 
analysis showed a possible association between 
pyrexia and exposure to the hydroxy-dabrafenib 
metabolite and, to a lesser extent, to dabrafenib 
in the two study groups. Similarly, trametinib ex-
posure was associated with pyrexia in the combi-
nation group (see the Methods and Results sec-
tions and Fig. S4 and S5 in the Supplementary 
Appendix).
Grade 3 or 4 adverse events occurred in 73 pa-
tients (35%) in the dabrafenib–trametinib group 
and 79 patients (37%) in the dabrafenib-only 
group. Noncutaneous cancers and new primary 
melanomas were uncommon (Table S3 in the 
Supplementary Appendix). Four deaths related 
to adverse events occurred in the dabrafenib–
trametinib group: three from cerebral hemor-
rhage (two during receipt of study treatment and 
one 5 days after cessation) and one from pneu-
monia (22 days after cessation of treatment). All 
four events were considered by the investigator 
to be unrelated to study treatment. No deaths 
related to adverse events occurred in the dab-
rafenib-only group (Table S3 in the Supplemen-
tary Appendix).
Discussion
In this phase 3 study, we found a significant 25% 
relative reduction in the risk of disease progres-
sion among patients with metastatic melanoma 
with BRAF V600E or V600K mutations who re-
ceived first-line treatment with a combination of 
dabrafenib and trametinib, as compared with 
dabrafenib alone. The combination therapy, as 
compared with monotherapy, was associated with 
a 37% relative reduction in the risk of death at 
the interim survival analysis, but this result did 
not cross the prespecified stopping boundary. 
Notably, this difference in survival was observed 
despite the increased use of new therapies after 
the discontinuation of monotherapy, including 
therapies with a proven survival benefit (e.g., ipi-
limumab).20,21 The overall response rate was also 
significantly higher in the group receiving both 
dabrafenib and trametinib. Resistance to single-
agent BRAF inhibition is acquired predominantly 
through reactivation of the MAPK pathway.5-7,22-26 
Our study shows that the inhibition of the MAPK 
pathway at two nodes rather than one decreases 
the risk of progression (and therefore delays re-
sistance) by 25%.
In a post hoc subgroup analysis, we found 
that patients with poorer prognostic features ap-
peared to benefit more from a combination of 
dabrafenib and trametinib than did those in the 
overall study population. At the time of the in-
terim survival analysis, patients with an elevated 
lactate dehydrogenase level who received the 
combination therapy, as compared with mono-
therapy, had a 52% relative reduction in the risk 
of death (hazard ratio, 0.48). Since events tend 
to occur earlier in patients with poorer prognos-
tic features, longer follow-up will be required to 
assess the effects of combination therapy as com-
pared with monotherapy in patients with better 
prognostic features, such as a normal lactate 
dehydrogenase level or stage M1a or M1b mela-
noma (i.e., only distant skin, subcutaneous, or 
nodal metastases or lung metastases).
Our study used a control regimen that had a 
proven survival benefit.2 It had a double-blind 
design and did not allow crossover at the time of 
progression. In addition, the median progres-
sion-free survival of 8.8 months in the dab-
rafenib-only group was longer than that in pre-
vious trials of dabrafenib and vemurafenib in 
which the median progression-free survival was 
5.5 to 6.9 months.1-4,17,27-29 The long plateau at 
the median progression-free survival point in 
the dabrafenib-only group may account in part 
for its increased value in our study (Fig. 1A). In 
addition, the preplanned sensitivity analysis 
showed that the median progression-free survival 
for dabrafenib was unstable. Data for patients 
who had clinical progression or received a new 
anticancer therapy without radiographic evi-
dence of progression were censored (which oc-
curred more frequently in the dabrafenib-only 
group than in the combination-therapy group in 
the first 2 months of the study). Thus, the me-
dian progression-free survival for the dabrafenib 
group decreased from 8.8 months to 7.6 months 
when clinical progression was included as an 
event and decreased from 8.8 months to 7.2 
months when receipt of a new anticancer thera-
py was included.
Patients receiving the combination therapy re-
quired more dose modifications than did those 
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receiving monotherapy. There was no significant 
between-group difference in the frequency of 
adverse events, including grade 3 and 4 toxic ef-
fects. However, the types of toxic effects differed. 
Hyperproliferative cutaneous events, including 
cutaneous squamous-cell carcinoma and other 
events related to paradoxical activation of the 
MAPK pathway, which show the oncogenic po-
tential of BRAF inhibitors,11-13 were significantly 
abrogated by the addition of the MEK inhibitor 
trametinib.12 There were no deaths in either 
study group that were considered by the investi-
gators to be related to treatment.
Pyrexia occurred more frequently in the com-
bination group than in the monotherapy group 
and was the most common reason for treatment 
discontinuation. Although there was an apparent 
relationship between pyrexia and exposure to 
the hydroxy-dabrafenib metabolite and trametinib 
in this study, the cause of pyrexia remains un-
known. Pyrexia has been shown to respond well 
to immediate temporary cessation of dabrafenib 
or both dabrafenib and trametinib, which were 
restarted once the patient was well and afebrile 
for at least 24 hours; prophylactic glucocorti-
coids may prevent recurrent episodes.30 The edu-
cation of patients regarding pyrexia and the need 
to interrupt treatment at the first sign of this 
side effect is critical to ensure that the episode 
is not prolonged or complicated by dehydration 
or hypotension.
In conclusion, in our study involving previous-
ly untreated patients who had metastatic mela-
noma with BRAF V600E or V600EK mutations, 
the combination of dabrafenib and trametinib, 
as compared with dabrafenib alone, reduced the 
risk of progression by 25% and improved the 
response rate. At the time of the interim analy-
sis, overall survival was longer in the combina-
tion group, but the prespecified stopping bound-
ary was not crossed.
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